Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

357
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
357
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

85
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
85
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

27
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
27
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

55
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
55
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

34
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
34
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

22
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
22

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Specific Metabolic Syndrome Combinations on Model-Estimated 10-Year Cardiovascular Risk in a Taiwanese Population.

Journal of clinical medicine·2026
Same author

High triglyceride-glucose index and changes in triglyceride-glucose index are associated with an increased risk of hypogonadism in middle-aged Taiwanese men: a retrospective longitudinal study.

Frontiers in endocrinology·2026
Same author

Certain Metabolic Syndrome Component Combinations are Linked to Increased Risk of Hypogonadism in Taiwanese Men.

Diabetes, metabolic syndrome and obesity : targets and therapy·2025
Same author

IgG4-related tubulointerstitial nephritis.

Annals of the rheumatic diseases·2023
Same author

The Presence of Diabetes Mellitus or Pre-diabetes Mellitus Increases Mortality from Heart Disease in a Taiwanese Population: A 10-year Follow-Up Study.

BMC cardiovascular disorders·2023
Same author

The Association between Serum Testosterone and Hyperuricemia in Males.

Journal of clinical medicine·2022

Related Experiment Video

Updated: Sep 20, 2025

Using Extraordinary Optical Transmission to Quantify Cardiac Biomarkers in Human Serum
09:23

Using Extraordinary Optical Transmission to Quantify Cardiac Biomarkers in Human Serum

Published on: December 13, 2017

6.4K

Troponin I Cutoff for Non-ST-Segment Elevation Myocardial Infarction in Sepsis.

Meng-Ko Tsai1,2,3, Chao-Hung Lai4, Chia-Lien Hung5

  • 1Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.

Mediators of Inflammation
|June 9, 2022
PubMed
Summary

The optimal cardiac troponin I cutoff for diagnosing myocardial infarction in sepsis patients is 300 ng/L. This finding aids in identifying type 1 myocardial infarction (MI) in sepsis, improving diagnostic accuracy.

More Related Videos

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.8K
A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.4K

Related Experiment Videos

Last Updated: Sep 20, 2025

Using Extraordinary Optical Transmission to Quantify Cardiac Biomarkers in Human Serum
09:23

Using Extraordinary Optical Transmission to Quantify Cardiac Biomarkers in Human Serum

Published on: December 13, 2017

6.4K
A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.8K
A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.4K

Area of Science:

  • Cardiology
  • Critical Care Medicine
  • Biomarkers

Background:

  • Cardiac troponin I (cTnI) is a key biomarker for myocardial injury, but its diagnostic utility in sepsis remains unclear.
  • Sepsis can precipitate myocardial infarction, complicating diagnosis and management.
  • Optimal cutoff levels for cTnI in diagnosing type 1 myocardial infarction (MI) within septic populations require investigation.

Purpose of the Study:

  • To determine the optimal cutoff value of cardiac troponin I for diagnosing non-ST-segment elevation myocardial infarction (NSTEMI) with type 1 MI in patients with sepsis.
  • To evaluate the diagnostic performance of cTnI in this specific patient cohort.

Main Methods:

  • Retrospective analysis of 5,341 patients (excluding chronic kidney disease) from 2009-2019.
  • Focus on 277 patients with sepsis or septic shock, particularly the 123 with non-ST-segment elevation acute coronary syndrome (NSTE-ACS).
  • Utilized receiver-operating characteristic (ROC) curve analysis to identify the optimal cTnI cutoff value.

Main Results:

  • Among 123 patients with NSTE-ACS and sepsis, 77 (62.6%) had type 1 MI.
  • The optimal cTnI cutoff for diagnosing type 1 MI in sepsis was determined to be >300 ng/L (AUC: 0.705, sensitivity: 68.4%, specificity: 70.2%).
  • No significant predictors for NSTEMI with type 1 MI were identified via multiple linear regression. cTnI and GRACE scores showed comparable predictive value for 6-month mortality.

Conclusions:

  • A cardiac troponin I cutoff of 300 ng/L is recommended for diagnosing type 1 myocardial infarction in patients with sepsis.
  • This established cutoff can enhance diagnostic accuracy for myocardial infarction in septic patients.
  • Further research may explore predictors of MI in sepsis and refine risk stratification strategies.